Jon Napitupulu

PureTech Health presented positive Phase 1b trial data for LYT-200, a novel anti-galectin-9 monoclonal antibody, in patients with relapsed...

Arcellx, a biotechnology company, announced positive Phase 2 iMMagine-1 study data for anitocabtagene autoleucel (anito-cel), a CAR T-cell therapycell...

Indapta Therapeutics and Sanofi are collaborating to investigate the combined efficacy and safety of Indapta’s allogeneic g-NK cell therapy,...

A new study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) demonstrates that a donor search...

Merck announced positive Phase 2 trial data for zilovertamab vedotin, an investigational antibody-drug conjugate targeting ROR1, in combination with...

Orca Bio presented positive three-year follow-up data for its allogeneic T-cell immunotherapy, Orca-T, at the 66th American Society of...

Vertex Pharmaceuticals announced long-term data from global clinical trials of CASGEVY, a CRISPR/Cas9 gene-edited therapy, for severe sickle cellsickle...

Kite, a Gilead Company, presented three analyses of Yescarta (axicabtagene ciloleucel) at the 66th American Society of Hematology (ASH)...

Bluebird bio announced updated data from its LYFGENIA gene therapy for sickle cellsickle cell disease (SCD) patients with a...

Innate Pharma and the Institute for Follicular Lymphoma (IFLI) have partnered to explore the potential of IPH6501, Innate’s anti-CD20...